AAAAAA
Results: 1-25/31
Authors:
Druker, BJ
Citation: Bj. Druker, Current treatment approaches for chronic myelogenous leukemia, CANCER J, 7, 2001, pp. S14-S18
Authors:
Guris, DL
Fantes, J
Tara, D
Druker, BJ
Imamoto, A
Citation: Dl. Guris et al., Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome, NAT GENET, 27(3), 2001, pp. 293-298
Authors:
Mauro, MJ
Druker, BJ
Citation: Mj. Mauro et Bj. Druker, Chronic myelogenous leukemia, CURR OPIN O, 13(1), 2001, pp. 3-7
Authors:
O'Dwyer, ME
Druker, BJ
Citation: Me. O'Dwyer et Bj. Druker, Chronic myelogenous leukaemia - new therapeutic principles, J INTERN M, 250(1), 2001, pp. 3-9
Authors:
Mauro, MJ
O'Dwyer, ME
Druker, BJ
Citation: Mj. Mauro et al., ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy, CANC CHEMOT, 48, 2001, pp. S77-S78
Authors:
Buchdunger, E
Matter, A
Druker, BJ
Citation: E. Buchdunger et al., Bcr-Abl inhibition as a modality of CML therapeutics, BBA-REV CAN, 1551(1), 2001, pp. M11-M18
Authors:
Hochhaus, A
Kreil, S
Corbin, A
La Rosee, P
Lahaye, T
Berger, U
Cross, NCP
Linkesch, W
Druker, BJ
Hehlmann, R
Citation: A. Hochhaus et al., Roots of clinical resistance to STI-571 cancer therapy, SCIENCE, 293(5538), 2001, pp. NIL_1-NIL_3
Authors:
Druker, BJ
Citation: Bj. Druker, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe Philadelphia chromosome (vol 344, pg 1038, 2001), N ENG J MED, 345(3), 2001, pp. 232-232
Authors:
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
Citation: Bj. Druker et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia., N ENG J MED, 344(14), 2001, pp. 1031-1037
Authors:
Druker, BJ
Sawyers, CL
Kantarjian, H
Resta, DJ
Reese, SF
Ford, JM
Capdeville, R
Talpaz, M
Citation: Bj. Druker et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe philadelphia chromosome., N ENG J MED, 344(14), 2001, pp. 1038-1042
Authors:
Druker, BJ
Citation: Bj. Druker, Imatinib - A viewpoint by John M. Goldman, DRUGS, 61(12), 2001, pp. 1775-1776
Authors:
Grumbach, IM
Mayer, IA
Uddin, S
Lekmine, F
Majchrzak, B
Yamauchi, H
Fujita, S
Druker, BJ
Fish, EN
Platanias, LC
Citation: Im. Grumbach et al., Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells, BR J HAEM, 112(2), 2001, pp. 327-336
Authors:
Goldman, JM
Druker, BJ
Citation: Jm. Goldman et Bj. Druker, Chronic myeloid leukemia: current treatment options, BLOOD, 98(7), 2001, pp. 2039-2042
Authors:
O'Dwyer, ME
Druker, BJ
Citation: Me. O'Dwyer et Bj. Druker, Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia, CURR OPIN O, 12(6), 2000, pp. 594-597
Authors:
Alsayed, Y
Modi, S
Uddin, S
Mahmud, N
Druker, BJ
Fish, EN
Hoffman, R
Platanias, LC
Citation: Y. Alsayed et al., All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells, EXP HEMATOL, 28(7), 2000, pp. 826-832
Authors:
Wilbanks, AM
Mahajan, S
Frank, DA
Druker, BJ
Gilliland, DG
Carroll, M
Citation: Am. Wilbanks et al., TEL/PDGF beta R fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins, EXP HEMATOL, 28(5), 2000, pp. 584-593
Authors:
Rhodes, J
York, RD
Tara, D
Tajinda, K
Druker, BJ
Citation: J. Rhodes et al., CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells, EXP HEMATOL, 28(3), 2000, pp. 305-310
Authors:
Gaston, I
Stenberg, PE
Bhat, A
Druker, BJ
Citation: I. Gaston et al., Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abltransformed cells (vol 28, pg 77, 2000), EXP HEMATOL, 28(3), 2000, pp. 351-351
Authors:
Gaston, I
Stenberg, PE
Bhat, A
Druker, BJ
Citation: I. Gaston et al., Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abltransformed cells, EXP HEMATOL, 28(1), 2000, pp. 77-86
Authors:
Buchdunger, E
Cioffi, CL
Law, N
Stover, D
Ohno-Jones, S
Druker, BJ
Lydon, NB
Citation: E. Buchdunger et al., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors, J PHARM EXP, 295(1), 2000, pp. 139-145
Authors:
Rao, N
Lupher, ML
Ota, S
Reedquist, KA
Druker, BJ
Band, H
Citation: N. Rao et al., The linker phosphorylation site Tyr(292) mediates the negative regulatory effect of Cbl on ZAP-70 in T cells, J IMMUNOL, 164(9), 2000, pp. 4616-4626
Authors:
Alsayed, Y
Uddin, S
Ahmad, S
Majchrzak, B
Druker, BJ
Fish, EN
Platanias, LC
Citation: Y. Alsayed et al., IFN-gamma activates the C3G/Rap1 signaling pathway, J IMMUNOL, 164(4), 2000, pp. 1800-1806
Authors:
Druker, BJ
Lydon, NB
Citation: Bj. Druker et Nb. Lydon, Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J CLIN INV, 105(1), 2000, pp. 3-7
Authors:
Thiesing, JT
Ohno-Jones, S
Kolibaba, KS
Druker, BJ
Citation: Jt. Thiesing et al., Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells, BLOOD, 96(9), 2000, pp. 3195-3199
Authors:
Heinrich, MC
Griffith, DJ
Druker, BJ
Wait, CL
Ott, KA
Zigler, AJ
Citation: Mc. Heinrich et al., Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor, BLOOD, 96(3), 2000, pp. 925-932